Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100021/S129

Endurant Stent Graft System, Endurant II Stent Graft System, Endurant IIs Stent Graft System

Medtronic Vascular · Decision date Sep 15, 2025

FDA DECISIONP100021/S129

What did the FDA approve?

FDA records P100021/S129 as a supplement to PMA P100021, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Sep 15, 2025.

FDA approval order statement

Approval to remove a warning from the device labeling regarding lack of safety and effectiveness data on the use of your device in emergency treatment of aneurysms, as well as a brief summary of the supportive data with regard to treatment of ruptured aneurysms.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Sep 15, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P100021/S129
Regulatory pathway
PMA supplement
Product code
MIH
Decision code
APPR
Decision date
Sep 15, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT.

Product code
MIH
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P100021/S129 received

    Application receipt date recorded by FDA.

  2. P100021/S129 · FDA decision

    Real-Time Process

  3. P100021/S131 · Related supplement

    Endurant II/IIs Stent Graft System

  4. P100021/S133 · Related supplement

    Endurant Stent Graft System; Endurant II/IIs Stent Graft System; Endurant II AUI Stent Graft System

  5. P100021/S134 · Related supplement

    Endurant, Endurant II/lls Stent Graft System

  6. P100021/S132 · Related supplement

    Endurant II/IIs Stent Graft System

Timeline entries are records held by MedtechLedger for P100021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100021

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic VascularPMA supplementOct 23, 2025FDA
Medtronic VascularPMA supplementJan 27, 2026FDA
Medtronic VascularPMA supplementFeb 27, 2026FDA
Medtronic VascularPMA supplementMay 12, 2026FDA

Explore the linked device profile

Other records with product code MIH

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Vascular

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3576 Unocal Pl., Santa Rosa, CA, 95403

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records